4 completed, 1 active not recruiting, 1 not yet recruiting. 6 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 4, Active not recruiting 1, Not yet recruiting 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Stage III Gastric Cancer: new trials by email Literature Review of Stage III Gastric Cancer trials Research Report on Stage III Gastric Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Megestrol Acetate Oral Suspension for Cachexia in Patients With cStage III Gastric/Gastroesophageal Junction Adenocarcinoma Receiving Neoadjuvant Therapy With Serplulimab Combined With SOX megestrol acetate oral suspension + serplulimab + SOX, serplulimab + SOX - Stage III Gastric Cancer | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 48 | 2026-02-15 | 2026-02-06 |
| TAS102 in Combination With NAL-IRI in Advanced GI Cancers Nanoliposomal Irinotecan, Trifluridine and Tipiracil Hydrochloride - Colorectal Adenocarcinoma, Gastric Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | Emory University | 64 | 2018-01-30 | 2025-01-07 |
| Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer saracatinib - Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach | Phase 2 | Completed | National Cancer Institute (NCI) | 21 | 2008-01-01 | 2018-08-23 |
| S0413 Lapatinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer lapatinib ditosylate, laboratory biomarker analysis - Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach | Phase 2 | Completed | National Cancer Institute (NCI) | 40 | 2004-12-01 | 2013-01-17 |
| Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction Cisplatin, Computed Tomography, Fludeoxyglucose F-18 - Gastric Adenocarcinoma, Stage II Gastric Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 55 | 2003-06-01 | 2017-07-06 |
| Bryostatin 1 and Cisplatin in Treating Patients With Metastatic or Unresectable Stomach Cancer bryostatin 1, cisplatin, laboratory biomarker analysis - Stage III Gastric Cancer, Stage IV Gastric Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 12 | 2000-10-01 | 2014-10-01 |
Stomach Neoplasms (6) · Colorectal Neoplasms (1) · Esophageal Neoplasms (1) · Pancreatic Neoplasms (1)
Digestive System Diseases (6) · Digestive System Neoplasms (6) · Gastrointestinal Diseases (6) · Gastrointestinal Neoplasms (6) · Neoplasms (6) · Neoplasms by Site (6) · Stomach Diseases (6) · Colonic Diseases (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Esophageal Diseases (1) · Head and Neck Neoplasms (1) · Intestinal Diseases (1) · Intestinal Neoplasms (1) · Pancreatic Diseases (1)
Cisplatin (2) · Irinotecan (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · Bryostatins (1) · Fluorodeoxyglucose F18 (1) · Lapatinib (1) · Magnetic Resonance Spectroscopy (1) · N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine (1) · Platinum (1) · Trifluridine (1) · alovudine (1) · bryostatin 1 (1) · irinotecan sucrosofate (1) · saracatinib (1) · trifluridine tipiracil drug combination (1)
National Cancer Institute (NCI) (4) · Emory University (1) · The First Affiliated Hospital with Nanjing Medical University (1)
United States (5) · Canada (1) · China (1)
Heather-Jane Au (1) · Heinz-Josef Lenz (1) · Manisha Shah (1) · Olatunji B. Alese, MD (1) · Syma Iqbal (1)
N01CM17101 (1), N01CM62203 (1), P30CA008748 (1)